首页> 外文OA文献 >Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma:Results from the Danish Renal Cancer Group (DARENCA) study-2

【2h】

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma:Results from the Danish Renal Cancer Group (DARENCA) study-2

机译：转移性肾细胞癌患者实施靶向治疗后改善的总生存期：丹麦肾癌小组（DARENCA）研究2的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

To evaluate the implementation of targeted therapy on overall survival (OS) in a complete national cohort of patients with metastatic renal cell carcinoma (mRCC).

机译：在一个完整的全国转移性肾细胞癌（mRCC）患者队列中评估靶向治疗对总生存期（OS）的实施情况。

著录项

作者
Soerensen, Anne V; Donskov, Frede; Hermann, Gregers; Jensen, Niels V; Petersen, Astrid; Spliid, Niels Henrik; Sandin, Rickard; Fode, Kirsten; Geertsen, Poul Flemming;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2 [J] . SoerensenA.V., DonskovF., HermannG.G., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第3期

机译：转移性肾细胞癌患者实施靶向治疗后改善的总生存期：丹麦肾癌小组（DARENCA）研究2的结果
2. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2 [J] . SoerensenA.V., DonskovF., HermannG.G., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第3期

机译：改善靶向肾细胞癌患者的靶向治疗后的整体存活：丹麦肾癌群（Darenca）研究结果 - 2
3. Registrations of Patients with Renal Cell Carcinoma in the Nationwide Danish Renal Cancer Database versus the Danish Cancer Registry: Data Quality, Completeness and Survival (DaRenCa Study-3) [J] . Bolette Danckert, Trine Allerslev Horsb?l, Ole Andersen, Clinical Epidemiology . 2020,第1期

机译：全国丹麦肾癌数据库中肾细胞癌患者的注册与丹麦癌症登记处：数据质量，完整性和生存（Darenca Study-3）
4. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
5. Methodological Approaches for Conducting Claims-Based Studies in Patients Diagnosed with Metastatic Renal Cell Carcinoma [D] . Chun, Danielle S. 2021

机译：用于诊断转移性肾细胞癌的患者的基于权利要求的基于权利要求的方法论方法
6. Registrations of Patients with Renal Cell Carcinoma in the Nationwide Danish Renal Cancer Database versus the Danish Cancer Registry: Data Quality Completeness and Survival (DaRenCa Study-3) [O] . Bolette Danckert, Trine Allerslev Horsbøl, Ole Andersen, 2020

机译：全国丹麦肾癌数据库中肾细胞癌患者的注册与丹麦癌症登记处：数据质量完整性和生存（Darenca Study-3）
7. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma:results from the Danish Renal Cancer Group (DARENCA) study-2 [O] . Soerensen, Anne V, Donskov, Frede, Hermann, Gregers G, 2014

机译：改善转移性肾细胞癌患者靶向治疗后的总生存率提高：丹麦肾癌组（DaRENCa）研究结果-2

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma:Results from the Danish Renal Cancer Group (DARENCA) study-2

摘要

著录项

相似文献

相关主题

期刊订阅